U.S. Food and Drug Administration (FDA) approved Novartis’s Sandoz drug Erelzi (biosimilar copy of Amgen’s Enbrel) on Tuesday but it remains blocked by court battles between the two giant drug makers. Read article here…..
Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.